Arcadia Biosciences Logo
US0390142042
A2JSFW
RKDA

Arcadia Biosciences

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 5,47 € (+3 117,65 %). La médiane est de 5,47 € (+3 117,65 %).

Acheter
  4
Conserver
  1
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Plus sur de.investing.com


  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Plus sur de.investing.com


  • Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

    Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Plus sur de.investing.com


  • Arcadia Biosciences stock rises after termination of Roosevelt deal

    Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Plus sur de.investing.com


  • Arcadia Biosciences schedules annual general meeting for December 19, 2025

    Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Arcadia Biosciences a réalisé un chiffre d'affaires de 1,43 M € et un bénéfice net de 1,55 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 1,43 M 28,83 %
Bénéfice brut 758,37 k 112,91 %
Bénéfice net 1,55 M 112,41 %
EBITDA 1,55 M 111,92 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
281,57 k €
Nombre d'actions
1,55 M
Plus haut/bas sur 52 semaines
3,53 € - 0,10 €
Dividendes Non
Bêta
0,59
Ratio P/E
-0,02
Ratio PEG
0,00
Ratio P/B
0,50
Ratio P/S
0,06

Profil de l'entreprise

Arcadia Biosciences, Inc. produit et commercialise des produits de santé et de bien-être à base de plantes aux États-Unis. Elle développe principalement des améliorations génétiques du blé afin d'optimiser la rentabilité des exploitations agricoles, en améliorant les performances des cultures au champ ainsi que leur valeur en tant qu'ingrédients alimentaires, leur intérêt pour les produits de santé et de bien-être, et leur viabilité pour des applications industrielles. La société a été constituée en 2002 et a son siège social à Davis, en Californie.

Nom
Arcadia Biosciences
PDG
Thomas J. Schaefer
Siège social Davis, tx
États-Unis
Site web
Secteur
Consommation de base
Industrie
Produits alimentaires
Introduction en bourse
15/05/2015
Employés 8

Symboles boursiers

Bourse Symbole
NASDAQ
RKDA
Frankfurt
17DN.F
München
17DN.MU
🍪

Parqet  utilise des cookies. En savoir plus